



**Stephen Earl Pratt, M.D.**  
West Coast Research LLC  
2301 Camino Ramon, Suite 290  
San Ramon, California 94583

Phone: (925) 866-7090  
Fax: (925) 866-3930

## EDUCATION

1995	Doctor of Medicine	University of Kansas School of Medicine, Kansas City, Kansas Alpha Omega Alpha Honor Medical Society
1991	B.S. in Biology	University of California, Los Angeles, California

## TRAINING

1995 – 1998	Residency	Mayo Graduate School of Medicine, Rochester, Minnesota
2007	TCW	GCP/ICH/Belmont, monthly training, newsletters
2007	OHRP	Human Subject Assurance Training, ICF and Investigators role
2007	ACRP	GCP/ICH Obligations of Investigators, Sponsors and Monitors
2008	CITI	Human Subjects Research Training

## LICENSURE AND CERTIFICATION

License	State of California #C51826 exp. 12/31/2010
Certificate	Diplomate, American Board of Internal Medicine 1998
Certificate	Controlled Substance Registration Certificate DEA Registration # BP5146255
Certificate	Certificate of Coverage and Claims Policy #704994 Norcal Mutual Insurance Company

## MEDICAL EXPERIENCE

2007 – Present	Physician Investigator, West Coast Research, Inc., San Ramon, California
2005 – Present	Internist, Private Practice, Oak Tree Internal Medicine, San Ramon, California
1998 – 2005	Internist, Grants Pass Clinic, Grants Pass, Oregon

## OFFICES AND POSITION

2006 – Present    Councilor, Alameda-Contra Costa Medical Association

## HOSPITAL STAFF

Active Staff at San Ramon Regional Medical Center, San Ramon, California  
Previous Staff at Three Rivers Community Hospital, Grants Pass Oregon

## PROFESSIONAL AND ACADEMIC APPOINTMENTS

American College of Physicians  
Alameda-Contra Costa Medical Association  
California Medical Association  
American Medical Association

**PH:** 925-866-7090

**FX:** 925-866-3930

**EMAIL:** [spratt@westcoastresearch.com](mailto:spratt@westcoastresearch.com)

**WEB:** [www.westcoastresearch.com](http://www.westcoastresearch.com)



## CLINICAL RESEARCH EXPERIENCE

- 1) A Randomized, Double-Blind, Active-Controlled, Parallel Group, Multicenter Study Comparing the proportion of Subjects with Stage 1 or 2 Essential Hypertension Who Achieve Target Blood Pressure While Receiving Either XXXX + XXXX or XXXX
- 2) A Prospective Descriptive, Multi-national, Multi-Centre Observational Study of Burden of Upper GI-Symptoms in Subjects with Cardiovascular Risk or Disease Receiving Treatment with Low-Dose Aspirin
- 3) A Phase 3 Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXX in Subjects with Uncomplicated Acute Influenza
- 4) A Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of XXX When compared with XXXX and XXXX in Subjects with Essential Hypertension
- 5) A Clinical Outcomes Study of XXXX versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
- 6) A Randomized, Double-Blind, Multiple-Site, Placebo Controlled, Parallel Design, Clinical Study to Evaluate the Bioequivalence of XXXX Compared to XXXX in Patients with Actinic Keratosis
- 7) A Randomized, Double-Blind, Controlled, Parallel group, 12-week treatment study to compare the efficacy and safety of the combination of XXXX daily with XXXX once daily versus open label XXXX once daily in patients with moderate-to-severe chronic obstructive pulmonary disease
- 8) Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Comparative Study of XXXX vs. XXXX in Patients with Herpes Zoster
- 9) A randomized, double-blind, placebo-controlled, multi-centre phase IIb dose finding study to assess the effect on GERD symptoms, safety and tolerability during four weeks treatment with XXXX in doses 60 mg, 120 mg, 180 mg and 240 mg bid as add-on treatment to a PPI in patients with GERD that are partial responders to PPI treatment
- 10) A Randomized, Double-blind, Placebo-Controlled Comparison of the Effects of Two Doses of XXXX or XXXX on Glycemic Control in Patients with Type 2 Diabetes on Stable Doses of XXXX and XXXX.
- 11) A Double Blind Placebo Study to determine the effectiveness of XXXX on the management of chronic back pain
- 12) A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety and Efficacy of XXXX and XXXX in Subjects With Cardiovascular Comorbidities, Hyperuricemia, and Gout.



- 13) A Phase 3b Multicenter, Single-Blind Trial to Evaluate the Efficacy of XXXX in Maintaining Control of Gastroesophageal Reflux Disease.
- 14) A 24-week, multicentre, randomized, double-blind, age-stratified, placebo controlled phase III study with a 28-week extension period to evaluate the efficacy and safety of XXXX 10 mg once daily in patients with type 2 diabetes, cardiovascular disease and hypertension, who exhibit inadequate glycaemic control on usual care.